CD Genomics delivers longitudinal TCR clonal tracking across the full TIL therapy manufacturing cycle — from tumor biopsy through REP expansion to peripheral blood PK monitoring — with ICH Q2(R1)-validated methodology aligned to EMA guidance on TIL product CQA requirements.

• Clone-level molecular identity from biopsy to final product
• Quantitative tracking of tumor-reactive TCR clones through REP
• Validated precision, accuracy, and sensitivity per ICH Q2(R1)
• IND-ready data package with formatted regulatory reports